Buprenorphine treatment of refractory depression
Bodkin JA, Zornberg GL, Lukas SE, Cole JO
McLean Hospital, Consolidated Department of Psychiatry,
Harvard Medical School, Belmont, MA 02178, USA.
J Clin Psychopharmacol 1995 Feb; 15(1):49-57
ABSTRACTOpiates were used to treat major depression until the mid-1950s. The advent of opioids with mixed agonist-antagonist or partial agonist activity, with reduced dependence and abuse liabilities, has made possible the reevaluation of opioids for this indication. This is of potential importance for the population of depressed patients who are unresponsive to or intolerant of conventional antidepressant agents. Ten subjects with treatment-refractory, unipolar, nonpsychotic, major depression were treated with the opioid partial agonist buprenorphine in an open-label study. Three subjects were unable to tolerate more than two doses because of side effects including malaise, nausea, and dysphoria. The remaining seven completed 4 to 6 weeks of treatment and as a group showed clinically striking improvement in both subjective and objective measures of depression. Much of this improvement was observed by the end of 1 week of treatment and persisted throughout the trial. Four subjects achieved complete remission of symptoms by the end of the trial (Hamilton Rating Scale for Depression scores < or = 6), two were moderately improved, and one deteriorated. These findings suggest a possible role for buprenorphine in treating refractory depression.SAMe
Substance P inhibitors
Is morphine an antidepressant?
Nitric oxide synthase inhibitors
Nociceptin receptor antagonists
Morphine for endogenous depressives?